Mengxuan Zuo

机构：Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China · ORCID：0000-0003-3589-7316

发表论文 49 篇 · 总被引 553 次 · h-index 13

代表论文

• Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study (2023 · Signal Transduction and Targeted Therapy · 被引 128)
• A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapy (2023 · La radiologia medica · 被引 34)
• Microwave ablation versus liver resection for primary intrahepatic cholangiocarcinoma within Milan criteria: a long-term multicenter cohort study (2024 · EClinicalMedicine · 被引 25)
• Postprogression treatment of lenvatinib plus PD‐1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy (2023 · Cancer · 被引 19)
• Multimodal imaging-based prediction of recurrence for unresectable HCC after downstage and resection-cohort study (2024 · International Journal of Surgery · 被引 15)
• Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high risk: a propensity score matching study (2024 · International Journal of Surgery · 被引 14)